🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to scientists.

An International Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million infections annually. Particularly high rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs currently available.”

Health officials are increasingly worried about the surge in drug-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm Innoviva to see it through.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines two antibiotics. The trial involved nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have shared positive views. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed vital to lessen the impact of the illness for patients and to halt the transmission of extremely resistant gonorrhoea around the world.